JPND held an industry consultation meeting on May 16th, 2011 at the University of Milan, Italy.
The consultation brought together representatives from biotechnology, biopharmaceutical and diagnostic companies with specific interest in the neurodegenerative diseases that fall within the focus of the JPND research agenda.
The aim of the meeting was to ascertain; the key priorities and needs of industries active in the field of ND, the “industry view” on the priorities identified by the academic sector through the thematic workshops, and the specific requirements for collaborative activity with the academic sector and other stakeholders (funders, regulators, etc.).
Download the summary report on the meeting findings here.
Chairperson: Adriana Maggi, MIUR, Italy
Presentations: Click on the presentation title to download the slides (pdf)
1. Introduction to JPND – Adriana Maggi
2. Developing the SRA – Catherine Moody
3. Outcomes of the Thematic Workshops – Adriana Maggi
Participants
Mohammad S. Alavijeh | Managing Director | Pharmidex Pharmaceutical Ltd UK |
Mariangela Amoroso | Neuroscience and Immunoscience Area Head | Bristol Meyer Squibb |
John R. Atack | Senior Fellow, In Vitro Neuroscience | Janssen R&D, J&J Pharmaceutical |
Roberta Buti | Grant Manager | Chiesi Farmaceutici |
Stefano Bruni | Scientific Director | Genzyme |
Carla Caccia | Grant Manager | Newron Pharmaceuticals SpA |
Donatella Crippa | Head of Medical Affairs | Bayer Healthcare |
Milva D’Aronco | Country Leader, Alzheimer’s Disease | Pfizer, Italy |
Daniele D’Ilario | Medical & Scientific Relations CNS & Pain | Pfizer, Italy |
Béatrice David | Latin Europe Sales Manager | Caliper Life Science |
Grazia Dell’Agnello | Medical Advisor | Lilly, Italy |
Koen Dewaele | Alzheimer’s Programme Director | Innogenetics NV |
Sophie Dix | Senior Research Scientist, ND Drug Hunting Team | Lilly, UK |
Bruno Imbimbo | Head, CNS Research | Chiesi Farmaceutici |
Rainer Kuhn | Head of Neurodegeneration Research | Novartis Pharma AG |
Wally Landsberg | European Medical Lead, Neuroscience | Bristol Meyer Squibb |
Bertrand Loubaton | Director, Pharmaceutical & Academic Research Collaboration Academic Programs | GE HealthCare |
Fabio Maggioni | Diagnostic Imaging Medical Science Liaison | Bayer Healthcare |
Gareth Maher-Edwards | Director, Clinical Development | GlaxoSmithKline |
Francesco Moneta | Lead, Molecular Resonance Imaging | Bruker, Italy |
Pierangelo Morini | Deputy Administrator | Bruker, Italy |
Francois Nicolas | BioSignature Technology Leader | GE HealthCare |
Michael O’Neill | Senior Research Advisor, ND Drug Hunting Team | Lilly, UK |
Jan Torleif Pedersen | Section head, Bioinformatics | H. Lundbeck A/S |
Thomas Rooney | Ageing Therapeutic Strategic Unit, Head Translational Research Group | Sanofi-Aventis |
Patricia Salvati | VP Preclinical Research and Development | Newron Pharmaceuticals SpA |
Erik Wong | Director, External Science CNS Pain Innovative Medicine Unit | AstraZeneca Pharmaceuticals LP |
Sean Greatbanks | JPND Programme Administrator | MRC (UK) |
Adriana Maggi | JPND Executive Board Vice-Chair and Director, Centre of Excellence on NDD’s, Milan | MIUR (Italy) |
Catherine Moody | JPND Manager & Neurosciences and Mental Health Programme Manager | MRC (UK) |
Micol Zappa | JPND Programme Manager | MIUR (Italy) |